CompletedPhase 3NCT02371369
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
Studying Tenosynovial giant cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Daiichi Sankyo
- Principal Investigator
- Global Team LeaderDaiichi Sankyo
- Intervention
- Pexidartinib(drug)
- Enrollment
- 120 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2021
Study locations (30)
- Mayo Clinic, Scottsdale, Arizona, United States
- University of Southern California, Los Angeles, California, United States
- Stanford Cancer Center, Palo Alto, California, United States
- UCLA Medical Center, Santa Monica, California, United States
- Mayo Clinic Cancer Center, Jacksonville, Florida, United States
- Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- : Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- Mayo Clinic Cancer Center, Rochester, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- MD Anderson Cancer Center at Cooper, Camden, New Jersey, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Duke Cancer Center, Durham, North Carolina, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02371369 on ClinicalTrials.govOther trials for Tenosynovial giant cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07499362Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- RECRUITINGPHASE4NCT07315841Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor SurgeryShanghai Jiao Tong University Affiliated Sixth People's Hospital
- RECRUITINGNCT07075471Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With VimseltinibDeciphera Pharmaceuticals, LLC
- ACTIVE NOT RECRUITINGPHASE3NCT05417789Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)SynOx Therapeutics Limited
- ACTIVE NOT RECRUITINGPHASE3NCT05804045Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)Abbisko Therapeutics Co, Ltd
- ACTIVE NOT RECRUITINGPHASE3NCT05059262Study of Vimseltinib for Tenosynovial Giant Cell TumorDeciphera Pharmaceuticals, LLC
- ACTIVE NOT RECRUITINGPHASE2NCT04703322A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in JapanDaiichi Sankyo Co., Ltd.
- RECRUITINGNCT04635111A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) TreatmentDaiichi Sankyo